Article révisé par les pairs
Résumé : BACKGROUND: A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients. METHODS: Patients (n = 307, with 137 events after a median follow-up of 13.6 years) from five European centers were divided into high- and low-risk groups based on the gene signature classification and on clinical risk classifications. Patients were assigned to the gene signature low-risk group if their 5-year distant metastasis-free survival probability as estimated by the gene signature was greater than 90%. Patients were assigned to the clinicopathologic low-risk group if their 10-year survival probability, as estimated by Adjuvant! software, was greater than 88% (for estrogen receptor [ER]-positive patients) or 92% (for ER-negative patients). Hazard ratios (HRs) were estimated to compare time to distant metastases, disease-free survival, and overall survival in high- versus low-risk groups. RESULTS: The 70-gene signature outperformed the clinicopathologic risk assessment in predicting all endpoints. For time to distant metastases, the gene signature yielded HR = 2.32 (95% confidence interval [CI] = 1.35 to 4.00) without adjustment for clinical risk and hazard ratios ranging from 2.13 to 2.15 after adjustment for various estimates of clinical risk; clinicopathologic risk using Adjuvant! software yielded an unadjusted HR = 1.68 (95% CI = 0.92 to 3.07). For overall survival, the gene signature yielded an unadjusted HR = 2.79 (95% CI = 1.60 to 4.87) and adjusted hazard ratios ranging from 2.63 to 2.89; clinicopathologic risk yielded an unadjusted HR = 1.67 (95% CI = 0.93 to 2.98). For patients in the gene signature high-risk group, 10-year overall survival was 0.69 for patients in both the low- and high-clinical risk groups; for patients in the gene signature low-risk group, the 10-year survival rates were 0.88 and 0.89, respectively. CONCLUSIONS: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer.

Documents en relation

DI-fusion

  • Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial
    par Lopes Cardozo, Josephine JMN , Drukker, Caroline C.A. , Rutgers, Emiel Th , Schmidt, Marjanka K , Glas, Annuska M , Witteveen, Anke , Cardoso, Fatima , Piccart-Gebhart, Martine , Esserman, Laura J , Poncet, Coralie , Van't Veer, Laura
    Publication 2022-04
  • Obesity-associated changes in molecular biology of primary breast cancer.
    par Nguyen, Ha Linh , Geukens, Tatjana , Maetens, Marion , Aparicio, Samuel , Bassez, Ayse , Borg, Åke A. , Brock, Jane , Broeks, Annegien , Caldas, Carlos , Cardoso, Fatima , De Schepper, Maxim , Delorenzi, Mauro , Drukker, Caroline A , Glas, Annuska M , Green, Andrew R , Isnaldi, Edoardo , Eyfjörð, Jórunn , Khout, Hazem , Knappskog, Stian , Krishnamurthy, Savitri , Lakhani, Sunil R , Langerod, Anita , Martens, John W M , McCart Reed, Amy AE , Murphy, Leigh , Naulaerts, Stefan , Nik-Zainal, Serena , Nevelsteen, Ines , Neven, Patrick , Piccart, Martine , Poncet, Coralie , Punie, Kevin , Purdie, Colin , Rakha, Emad A , Richardson, Andrea , Rutgers, Emiel , Vincent-Salomon, Anne , Simpson, Peter T , Schmidt, Marjanka K , Sotiriou, Christos , Span, Paul N , Tan, Benita Kiat Tee BK , Thompson, Alastair , Tommasi, Stefania , Van Baelen, Karen , Van de Vijver, Marc , Van Laere, Steven , Van't Veer, Laura , Viale, Giuseppe , Viari, Alain , Vos, Hanne , Witteveen, Anke T , Wildiers, Hans , Floris, Giuseppe , Garg, Abhishek D , Smeets, Ann , Lambrechts, Diether , Biganzoli, Elia , Richard, François , Desmedt, Christine
    Publication 2023-07
  • First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.
    par De Caluwe, Alex , Romano, Emanuela , Poortmans, Philip , Gombos, Andrea , Agostinetto, Elisa , Marta, Guilherme Nader , Denis, Zoe , Drisis, Stylianos , Vandekerkhove, Christophe , Desmet, Antoine , Philippson, Catherine , Craciun, Ligia , Veys, Isabelle , Larsimont, Denis , Paesmans, Marianne , Van Gestel, Dirk , Salgado, Roberto , Sotiriou, Christos , Piccart-Gebhart, Martine , Ignatiadis, Michail , Buisseret, Laurence
    Publication 2023-12-01
  • Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00.
    par Joaquin Garcia, Andrea , Rediti, Mattia , Venet, David , Majjaj, Samira , Kammler, Roswitha , Munzone, Elisabetta , Gianni, Lorenzo , Thürlimann, Beat , Láng, I , Colleoni, Marco Angelo , Loi, Sherene , Viale, Giuseppe , Regan, Meredith M , Buisseret, Laurence , Rothé, Françoise , Sotiriou, Christos
    Publication 2023-09-01
  • PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
    par Amato, Ottavia , Buisseret, Laurence , Gebhart, Géraldine , Plouznikoff, Nicolas , Larsimont, Denis , Awada, Ahmad , Piccart-Gebhart, Martine , Aftimos, Philippe
    Publication 2023-05-01